Aesculap Biologics LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1867-01-01
- Employees
- 251
- Market Cap
- -
NOVOCART 3D Treatment Following Microfracture Failure
Phase 3
Active, not recruiting
- Conditions
- Articular Cartilage Defect
- Interventions
- Combination Product: NOVOCART 3D
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Aesculap Biologics, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT03219307
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Alpine Orthopaedics, North Logan, Utah, United States
NOVOCART®3D for Treatment of Articular Cartilage of the Knee
Phase 3
Active, not recruiting
- Conditions
- Articular Cartilage of the Femoral Condyle Between 2-6cm2
- Interventions
- Procedure: MicrofractureBiological: NOVOCART 3D
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Aesculap Biologics, LLC
- Target Recruit Count
- 233
- Registration Number
- NCT01957722
- Locations
- 🇺🇸
Grossmont Orthopaedic Medical Group, La Mesa, California, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Stanford Medicine, Redwood, California, United States
© Copyright 2025. All Rights Reserved by MedPath